ORIC News and Press, Oric Pharmaceuticals Inc.

2024-06-13 18:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-13 04:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-06 17:32:46 ET More on ORIC Pharmaceuticals ORIC Pharmaceuticals: Rally Seems Overdone ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains ORIC Pharmaceuticals GAAP EPS of -$0.49 Cantor starts ORIC at overweight, cites po...

Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC patients with EGFR exon 20 insertion, HER2 exon 20 insertion, or EGFR atypical mutations; updated Phase 1b data expected in the first half of 2025 Presented initial ORIC-944 Phase 1b monotherapy data demonstrating potential best...

2024-05-03 09:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations Additionally, the company initiated an extension cohort to evaluate ORIC-114 for the treatment of patients with first-line, treat...

ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a potential best-in-class profile versus competitor PRC2 inhibitors Preclinical synergy data in prostate cancer models reinforces th...

2024-03-29 05:29:56 ET Summary ORIC Pharmaceuticals' stock has seen significant gains since releasing promising data from its ORIC-114 program, which induced multiple partial responses in NSCLC patients. The company focuses on developing therapies to counter resistance mechanisms ...

2024-03-13 08:19:27 ET Summary ORIC Pharmaceuticals has reported positive preliminary results for three programs in its pipeline: ORIC-944, ORIC-114, and ORIC-533. ORIC-944, for the treatment of metastatic prostate cancer, is expected to initiate a combination study in the first h...

2024-03-12 14:15:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for ORIC on March 12, 2024 12:55PM ET. The previous analyst recommendation was Outperform. ORIC was trading at $14.62 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...